Stephen Davis Net Worth

The estimated Net Worth of Stephen Davis is at least $13.9 Milion dollars as of 16 August 2024. Mr. Davis owns over 31,747 units of Acadia Pharmaceuticals Inc stock worth over $2,975,552 and over the last 10 years he sold ACAD stock worth over $3,313,498. In addition, he makes $7,631,250 as Director and Chief Executive Officer at Acadia Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Davis ACAD stock SEC Form 4 insiders trading

Stephen has made over 31 trades of the Acadia Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 31,747 units of ACAD stock worth $485,094 on 16 August 2024.

The largest trade he's ever made was exercising 200,000 units of Acadia Pharmaceuticals Inc stock on 13 May 2020 worth over $3,930,000. On average, Stephen trades about 21,021 units every 56 days since 2014. As of 16 August 2024 he still owns at least 186,555 units of Acadia Pharmaceuticals Inc stock.

You can see the complete history of Mr. Davis stock trades at the bottom of the page.

Stephen Davis biography

Stephen R. Davis CPA serves as Director and Chief Executive Officer of the Company. He has served as our Chief Executive Officer and as a director of our company since September 2015. Mr. Davis joined us in July 2014 as our Executive Vice President, Chief Financial Officer and Chief Business Officer and served as our Interim Chief Executive Officer from March through August of 2015. Mr. Davis brings over 20 years of executive-level experience in the pharmaceutical industry. Prior to joining our company, he was Executive Vice President and Chief Operating Officer at Heron Therapeutics, Inc., which he joined in 2013, and Executive Vice President and Chief Operating Officer at Ardea Biosciences, Inc. from 2010 to 2013. Prior to joining Ardea, Mr. Davis served in numerous executive roles at Neurogen Corporation from 1994 to 2010, including Chief Executive Officer, Chief Operating Officer, and Chief Financial Officer. Mr. Davis currently serves on the board of directors of Bellicum Pharmaceuticals, Inc. and Heron Therapeutics, Inc. During the past five years, Mr. Davis served on the boards of directors of Heron Therapeutics and Synageva BioPharma Corp. Earlier in his career, Mr. Davis practiced as a certified public accountant with a major accounting firm and as a corporate and securities attorney with a Wall Street law firm. Mr. Davis received his Bachelor of Science degree in accounting from Southern Nazarene University and a Juris Doctorate from Vanderbilt University.

What is the salary of Stephen Davis?

As the Director and Chief Executive Officer of Acadia Pharmaceuticals Inc, the total compensation of Stephen Davis at Acadia Pharmaceuticals Inc is $7,631,250. There are no executives at Acadia Pharmaceuticals Inc getting paid more.

How old is Stephen Davis?

Stephen Davis is 59, he's been the Director and Chief Executive Officer of Acadia Pharmaceuticals Inc since 2019. There are 6 older and 10 younger executives at Acadia Pharmaceuticals Inc. The oldest executive at Acadia Pharmaceuticals Inc is Edmund Harrigan, 67, who is the Independent Director.

What's Stephen Davis's mailing address?

Stephen's mailing address filed with the SEC is C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO, CA, 92130.

Insiders trading at Acadia Pharmaceuticals Inc

Over the last 20 years, insiders at Acadia Pharmaceuticals Inc have traded over $21,409,958 worth of Acadia Pharmaceuticals Inc stock and bought 29,279,665 units worth $647,484,672 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp667, L.P.B... a Carl L Gordon. On average, Acadia Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $2,248,934. The most recent stock trade was executed by Mark C. Schneyer on 16 August 2024, trading 9,733 units of ACAD stock currently worth $148,720.

What does Acadia Pharmaceuticals Inc do?

acadia pharmaceuticals (nasdaq: acad) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (cns) disorders. all of acadia's product candidates emanate from internal discoveries. we believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. acadia’s history is rooted in science and strong leadership in cns research. our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. acadia is headquartered in san diego. the city represents the second largest biotechnology industry cluster in the united states, home to over 400 companies, as well as the salk institute for biological studies

Complete history of Mr. Davis stock trades at Acadia Pharmaceuticals Inc, Bellicum Pharmaceuticals Inc a Heron Therapeutics Inc

Acadia Pharmaceuticals Inc executives and stock owners

Acadia Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Stephen Davis,
  Director and Chief Executive Officer
• Srdjan Stankovic,
  President
• Michael Yang,
  Executive Vice President, Chief Commercial Officer
• Elena Ridloff,
  Executive Vice President, Chief Financial Officer
• Austin Kim,
  Executive Vice President, General Counsel, and Secretary
• Stephen R. Davis J.D.,
  CEO & Director
• Dr. Srdjan R. Stankovic,
  Pres
• Austin D. Kim,
  Exec. VP, Gen. Counsel & Sec.
• Daniel Soland,
  Independent Director
• James Daly,
  Independent Director
• Edmund Harrigan,
  Independent Director
• Stephen Biggar,
  Independent Chairman of the Board
• Laura Brege,
  Independent Director
• Julian Baker,
  Independent Director
• Mark Johnson,
  Vice President, Investor Relations
• Elizabeth Garofalo,
  Director
• James Kihara,
  Principal Accounting Officer
• Ponni Subbiah,
  Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer
• Mark Schneyer,
  Senior Vice President, Business Development and Chief Business Officer
• Stephanie Fagan,
  Senior Vice President - Corporate Affairs, Chief Communications Officer
• Gudarz Davar,
  Executive Vice President - Head of Research and Development
• Julie Fisher,
  Sr. VP of Marketing & Commercial Strategy
• Dr. Kathie M. Bishop Ph.D.,
  Sr. VP, Chief Scientific Officer & Head of Rare Disease
• Bob Mischler,
  Sr. VP of Strategy & Technology Operations
• James K. Kihara,
  VP, Corp. Controller & Principal Accounting Officer
• Brendan Teehan,
  Exec. VP, COO & Head of Commercial
• Bros. Advisors Lpbaker Feli...,
  
• Mary Ann Gray,
  Director
• Terrence O Moore,
  EVP, CHIEF COMMERCIAL OFFICER
• L.P.667, L.P.Baker Bros. Ad...,
  
• Leslie L Iversen,
  
• Bros. Advisors Lp667, L.P.B...,
  
• Bros. Advisors Lp14159, L.P...,
  
• Todd S. Young,
  EVP AND CFO
• Roger Mills,
  Executive VP, Development
• Uli Hacksell,
  Chief Executive Officer
• Michael T Borer,
  Director
• Thomas H Aasen,
  VP, CFO, Sec. Treas.
• Lester J Ph D Kaplan,
  Director
• Torsten Rasmussen,
  Director
• Robert E Davis,
  Exec. VP, Drug Discovery
• William Mc Dowall Wells,
  
• Bros Advisors Llcbaker Feli...,
  
• Bioscience Partners Iv Lpmr...,
  
• Osch Martien Van,
  Director
• Bioscience Partners Iv Lpob...,
  
• Carl L Gordon,
  Director
• Felixbaker Julianbaker Bros...,
  
• Mark R Brann,
  Pres., Chf. Scientific Officer
• Alan Walton,
  Director
• Glenn Baity,
  EVP AND GC
• Bo Ragnar Tolf,
  VP Chm/Mng Dir ACADIA Phrm A/S
• Gordon M Binder,
  Director
• Brian Lundstrom,
  Sr. VP. Business Development
• John Joseph Kaiser,
  VP, Strat. Mrkting & Com. Dev.
• Adora Ndu,
  
• Brendan Teehan,
  EVP, COO, HEAD OF COMMERCIAL
• Douglas J Williamson,
  Executive VP, Research & Dev
• Bros. Advisors Lp667, L.P.B...,
  
• Jennifer J Rhodes,
  EVP, CHIEF LEGAL OFFICER, SEC
• Elizabeth H.Z. Thompson,
  EVP, Head of Research & Dev